Clinical Trial Update: Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) [Phase 1]

View source ↗

Summary

Phase 1 study of a CD70-targeted chimeric antigen receptor (CAR) T-cell therapy named SEVENTY for acute leukemias; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• SEVENTY

Snippet

Sponsor: Baylor College of Medicine | Conditions: Leukemia, Myeloid, Acute, Leukemia, B-cell | Phase 1 | Status: NOT_YET_RECRUITING